Author:
Chen Mengfei,Li Haoze,Wu Yinxuan
Abstract
The problem of cancer is becoming more and more serious. As of 2021, the global of cancer patients has reached 14 million. Now how to treat cancer has become one of the key research topics. To treat cancer, people have found many cure methods, like salvage chemotherapy, radiotherapy, cytotoxic chemotherapy, and so on. But these therapies can only delay the patient's life. They cannot cure cancer. People want to find a therapy to completely empty the cancer cells. Until 1989, scientists have found a way to engineer T-cell called Chimeric antigen receptor T cell (CAR-T) to attack cancer cells, CAR-T therapy now has four generations. Good results have been achieved in the treatment of B-cell malignant lymphoma. However, CAR-T treatment in the area of solid tumors now still has many challenges. Therefore, the topic of this article is based on this structure of CAR-T cells, The development of CAR-T cell therapies and clinical application of CAR-T to reveal advantages and disadvantages of CAR-T treatment in cancer.
Publisher
Darcy & Roy Press Co. Ltd.
Reference34 articles.
1. Zhang C., Liu J., Zhong J. F., et al. Engineering CAR-T cells [J]. Biomark Res, 2017, 5: 22.
2. Firor A. E., Jares A., Ma Y. From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy [J]. Exp Biol Med (Maywood), 2015, 240 (8): 1087 - 1098.
3. Jiang Y., Wen W. H., Yang F., et al. Research Progress of Multi-target CAR-T Cell Therapy for Cancer [J]. Cancer Research on Prevention and Treatment, 2022, 49 (7): 709 - 714.
4. Whilding L. M., Maher J. CAR T-cell immunotherapy: The path from the by-road to the freeway? [J]. Mol Oncol, 2015, 9 (10): 1994 - 2018.
5. D'Aloia M. M., Zizzari I. G., Sacchetti B., et al. CAR-T cells: the long and winding road to solid tumors [J]. Cell Death Dis, 2018, 9 (3): 282.